Correlation Between Kymera Therapeutics and Eliem Therapeutics

Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kymera Therapeutics and Eliem Therapeutics, you can compare the effects of market volatilities on Kymera Therapeutics and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Eliem Therapeutics.

Diversification Opportunities for Kymera Therapeutics and Eliem Therapeutics

0.16

Correlation Coefficient

Kymera Therapeutics  Eliem Therapeutics

Average diversification

The 3 months correlation between Kymera and Eliem is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Eliem Therapeutics go up and down completely randomly.

Pair Corralation between Kymera Therapeutics and Eliem Therapeutics

Given the investment horizon of 90 days Kymera Therapeutics is expected to generate 0.66 times more return on investment than Eliem Therapeutics. However, Kymera Therapeutics is 1.52 times less risky than Eliem Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Eliem Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  4,707  in Kymera Therapeutics on September 4, 2024 and sell it today you would lose (16.00) from holding Kymera Therapeutics or give up 0.34% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	95.24%
Values	Daily Returns

Kymera Therapeutics  vs.  Eliem Therapeutics

Kymera Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Kymera Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable primary indicators, Kymera Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Kymera Therapeutics and Eliem Therapeutics

The main advantage of trading using opposite Kymera Therapeutics and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.

The idea behind Kymera Therapeutics and Eliem Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.